The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.115113 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Chiara Molinelli und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncolo…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Ma…
- U. O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
- Department of Oncology, ASU FC University Hospital, Udine, Italy.
- U.O.C. Oncologia, AORN Cardarelli, Napoli, Italy.
- UOSD Centro Oncologico S. Spirito e Nuovo Regina Margherita, ASL Roma 1, Rome, Italy.
Zitieren
APA
Molinelli, C., Bruzzone, M., Blondeaux, E., Ruelle, T., Lanzavecchia, C., De Laurentiis, M., Russo, S., Riccardi, F., Sini, V., Cognetti, F., Arpino, G., Fabi, A., Pugliese, P., Collovà, E., Fontana, A., Puglisi, F., Bighin, C., Lambertini, M., & Del Mastro, L. (2024). The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115113
Vancouver
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, et al. The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115113
BibTeX
@article{Molinelli2024,
author = {Molinelli, Chiara and Bruzzone, Marco and Blondeaux, Eva and Ruelle, Tommaso and Lanzavecchia, Chiara and De Laurentiis, Michelino and Russo, Stefania and Riccardi, Ferdinando and Sini, Valentina and Cognetti, Francesco and Arpino, Grazia and Fabi, Alessandra and Pugliese, Palma and Collovà, Elena and Fontana, Andrea and Puglisi, Fabio and Bighin, Claudia and Lambertini, Matteo and Del Mastro, Lucia},
title = {The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.115113}
}
EUVIMED